HOTH

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.